A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 111 participants.
Also called NCT07188805
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; triple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 111 participants
- Sponsor
- Registry
-
NCT07188805 -
2024-519829-38-00
-
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- United States, Argentina, Austria, Belgium, Brazil, Bulgaria, Canada, Czechia, Finland, Germany, Greece, Hungary, Israel, Italy, Mexico, Poland, Portugal, South Korea, Spain, Sweden, Taiwan, Türkiye, United Kingdom
- Registry status
- Recruiting
Technical summary
Registry record NCT07188805. Randomized; triple masking; primary purpose treatment. Start 2025-11-19 (actual); primary completion 2029-11-30 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- A Study to Learn More About How Well Finerenone Works, How Safe it is, and How it Moves Into, Through, and Out of the Body Compared to Placebo When Taken With Standard Treatment in Children With Heart Failure and Left Ventricular Systolic Dysfunction
- Acronym
- FIORE
- Condition
- Left Ventricular Systolic Dysfunction
- Condition
- Heart Failure (Pediatric)
- Intervention (Drug)
- Finerenone (Kerendia, BAY94-8862)
- Intervention (Drug)
- Placebo
- Lead sponsor
- Bayer
Record details
- Record id
cardio:ct-nct07188805- Content hash
17821fb1388534fc6d7c2fe5b843e336020f0c4814118e039e3b6ac97b5d8e64